Asian Spectator

5 Ways Small Businesses Can Benefit from Utilizing Cryptocurrencies

Over the last couple of years, cryptocurrencies have become a very important part of the financial landscape. Still, the alternative nature of these types of financial assets still keeps most of the small businesses on the fence about the whole matter. How can these assets benefit your organiz...

Eisai: New Fine Granule Formulation of Anti-epileptic Drug Fycompa Launched in Japan

Eisai: New Fine Granule Formulation of Anti-epileptic Drug Fycompa Launched in Japan

TOKYO, Jul 6, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has launched a new fine granule formulation of its in-house-discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) in Japan on July 6, 2020. Eisai received marketing and manufacturing approval for this formulation on January 23, 2020, and the fine granule formulation was added to Japan's National Health Insurance drug price list on April 23 of the same year.

In Japan, it is estimated that there are approximately 1 million patients with epilepsy. While epilepsy is a disease that may occur regardless of age, it is said that incidence is particularly high in children and the elderly. This newly launched fine granule formula was developed so that even patients who have difficulty taking tablets such as children or those who have difficulties in taking tablets due to reduced swallowing ability may take this drug. Additionally, greater ability to adjust dosage to match patients' symptoms becomes possible.

Fycompa is a first-in-class AED discovered at Eisai's Tsukuba Research Laboratories and was developed in-house. It is a highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation associated with seizures by targeting glutamate activity at postsynaptic AMPA receptors. In Japan, Fycompa is currently approved for monotherapy and adjunctive use in the treatment of partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy 4 years of age and older, as well as adjunctive treatment for primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older.With the launch of this fine granule formulation in Japan, Eisai will continue to prioritize the provision of safety information. Furthermore, Eisai will pursue its mission of delivering "seizure freedom" to as many patients as possible, and seek to address the diverse needs of, as well as increasing the benefits provided to, patients with epilepsy and their families.

About Eisai

Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com

Contact:Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Cellini Launches Interest Free Payment Plans As Singapore Enters Phase 2

SINGAPORE - Media OutReach - 6 August 2020 - Cellini Singapore eases budget constraints of existing and first-time homeowners with its interest-free instalment plan as locals continue t...

Adkins Zheng from Thousand Cities Strategic Algorithms (TCSA):...

SHENZHEN, China, Aug. 6, 2020 /PRNewswire-AsiaNet/ -- Mr. Adkins Zheng, Chairman and Chief Algorithm Officer of TCSA, shared a comprehensive overview of his company's mission, values and gra...

Tessa Therapeutics Announces Results from Two Independent Phas...

SINGAPORE, Aug. 6, 2020 /PRNewswire-AsiaNet/ -- Tessa Therapeutics (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments, today announced the publicatio...

Caprion-HistoGeneX and Viroclinics-DDL announce a strategic pa...

MONTREAL and ROTTERDAM, Netherlands, Aug. 7, 2020 /PRNewswire-AsiaNet/ -- -- Caprion-HistoGeneX, a specialized CRO providing immunology, proteomics, histopathology and genomics services, and...

CIIE: Larger, high-quality international import expo gearing u...

SHANGHAI, Aug. 6, 2020 /PRNewswire-AsiaNet/-- The third China International Import Expo, to be held as scheduled at the National Exhibition and Convention Center (Shanghai) in November, feat...

Celgard Successful in UK Court and is Granted Injunction Again...

CHARLOTTE, North Carolina, Aug. 7, 2020 /PRNewswire-AsiaNet/ -- Following the United Kingdom (UK) court's grant on May 7, 2020 of an interim injunction against Shenzhen Senior Technology Mat...

Cellini Launches Interest Free Payment Plans As Singapore Enters Phase 2

SINGAPORE - Media OutReach - 6 August 2020 - Cellini Singapore eases budget constraints of existing and first-time homeowners with its interest-free instalment plan as locals ...

Herbalife Nutrition Launches Vitamin Mask for Beautiful, Healt...

HONG KONG, Aug. 6,2020/PRNewswire-AsiaNet/-- Formulated with a proprietary blend, including a complex of 12 Vitamins, Aloe Vera, Jeju Sea Salt and Jeju Rice Extract Premier global nutrition ...

Magazine

Australian startup CareApp receives funding injection to expand app

Australian based startup CareApp has recently raised over $500,000 in funding including $250,000 provided by the South Australian State Government to rapidly expand and scale up their smartphone...

Shaparency launches to enable businesses to go fully digital

New venture developed for post-Covid-19 corporate landscape London-based start-up Shaparency, which has been established in response to the business conditions resulting from Covid-19, announces ...

Specops Significant Cyber Attacks

The prevalence and severity of cyber attacks are increasing at an alarming rate every year. So much so, that statistics from Cybersecurity Ventures estimate that cybercrime will cost the global ...



News Company Media Core

Content & Technology Connecting Global Audiences

More Information - Less Opinion

office@NewsCompany.net